Disease Landscape and Forecast Insights

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…

In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…

Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…

Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

Biomarker-driven prescribing is paramount in key oncology indications, particularly breast cancer, ovarian cancer, and prostate cancer. Key to all three indications are PARP inhibitors, such as…

Clarivate Epidemiology’s coverage of BRAF comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…

Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…